Markets›PPCB

Propanc Biopharma, Inc.

PPCB

0.6303

+0.0285 (+4.74%)

Closing price for Sep 25, 2026 from Polygon.io

A preclinical cancer treatment extended median survival more than 2.5-fold in animal models.
Stock Titan · Sep 22, 2026
Propanc Biopharma, Inc. FY 2026: Revenue $0 EPS $(17.62) — 10-K Summary
TradingView · Sep 25, 2026
PPCB 10-K & SEC Filings
Yahoo Finance · Sep 25, 2026
SpaceX IPO: Wall Street Titan BlackRock Reportedly Orders Massive $5B Stake
Stocktwits · Sep 26, 2026
Propanc Biopharma, Inc. (PPCB) Net Income 2026: $18.9M net loss, up 68.0%
Stock Titan · Sep 26, 2026

Headlines via Google News. Links open the original publisher.